Aurinia Pharmaceuticals Inc. (AUPH) 10-Year Financial Performance & Capital Metrics

AUPH •

HealthcareBiotechnologyImmunology and Inflammation Therapies

AboutAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Show more

Revenue $283M +20.4%
EBITDA $105M +610.9%
Net Income $287M +4893.1%
EPS (Diluted) 2.07 +5167.2%
Gross Margin 88.46% +0.5%
EBITDA Margin 37.06% +490.5%
Operating Margin 37.06% +1959.5%
Net Margin 101.47% +4047.7%
ROE 59.91% +3834.1%
ROIC 16.58% +1986.5%
Debt/Equity 0.13 -38.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 47.8% free cash flow margin
✓Strong 5Y sales CAGR of 41.4%
✓Share count reduced 5.1% through buybacks

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y103.27%

5Y41.38%

3Y28.3%

TTM20.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM4893.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM4615.26%

ROCE

10Y Avg-26.72%

5Y Avg-13.06%

3Y Avg-0.87%

Latest18.89%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	173K	420K	463K	318K	50.12M	45.6M	134.03M	175.51M	235.13M	283.06M
Revenue Growth %	-26.38%	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%
Cost of Goods Sold+	4K	1K	41.38M	0	0	1.09M	5.66M	14.15M	28.25M	32.66M
COGS % of Revenue	2.31%	0.24%	8937.8%	-	-	2.39%	4.23%	8.06%	12.01%	11.54%
Gross Profit+	169K	419K	-40.92M	318K	50.12M	44.51M	128.37M	161.37M	206.88M	250.39M
Gross Margin %	97.69%	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Gross Profit Growth %	-24.22%	147.93%	-9865.87%	100.78%	15660.38%	-11.18%	188.37%	25.71%	28.21%	21.03%
Operating Expenses+	22.98M	47.48M	56.62M	91.26M	154.41M	225.25M	239.84M	253.06M	211.57M	145.48M
OpEx % of Revenue	13284.97%	11305.24%	12229.16%	28698.43%	308.09%	493.91%	178.94%	144.18%	89.98%	51.4%
Selling, General & Admin	6.97M	12.1M	13.67M	22.34M	97.27M	171.44M	196.37M	195.04M	172.03M	101.79M
SG&A % of Revenue	4028.9%	2880%	2953.35%	7024.53%	194.09%	375.92%	146.51%	111.12%	73.16%	35.96%
Research & Development	14.53M	33.93M	41.38M	52.87M	50.33M	51.14M	44.99M	49.64M	20.79M	32.51M
R&D % of Revenue	8401.16%	8078.57%	8937.8%	16624.53%	100.42%	112.13%	33.57%	28.28%	8.84%	11.48%
Other Operating Expenses	-1.63M	195K	2.06M	16.06M	6.81M	2.67M	-1.52M	8.38M	18.76M	11.18M
Operating Income+	-22.81M	-47.06M	-56.16M	-90.94M	-104.29M	-180.74M	-111.47M	-91.69M	-4.69M	104.91M
Operating Margin %	-13187.28%	-11205.48%	-12129.16%	-28598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%	37.06%
Operating Income Growth %	3.25%	-106.29%	-19.33%	-61.94%	-14.68%	-73.3%	38.32%	17.74%	94.89%	2338.4%
EBITDA+	-21.34M	-45.61M	-54.59M	-89.77M	-102.92M	-177.97M	-108.76M	-80.04M	14.76M	104.91M
EBITDA Margin %	-12332.37%	-10858.81%	-11791.14%	-28230.19%	-205.35%	-390.25%	-81.15%	-45.61%	6.28%	37.06%
EBITDA Growth %	3.12%	-113.77%	-19.7%	-64.44%	-14.64%	-72.93%	38.89%	26.41%	118.44%	610.9%
D&A (Non-Cash Add-back)	1.48M	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	0
EBIT	-22.81M	-47.06M	-55.91M	-90.94M	-104.29M	-180.21M	-106.35M	-74.69M	12.28M	0
Net Interest Income+	27K	1.04M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	0
Interest Income	27K	1.04M	2.23M	2.7M	1.52M	529K	5.12M	17M	16.97M	13.57M
Interest Expense	0	0	0	0	0	0	0	2.77M	4.83M	-4.33M
Other Income/Expense	-481K	-23.73M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	9.24M
Pretax Income+	-23.3M	-70.79M	-64.05M	-88.24M	-102.77M	-180.21M	-106.35M	-77.47M	7.45M	114.16M
Pretax Margin %	-13465.32%	-16855.24%	-13833.05%	-27748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%	40.33%
Income Tax+	0	0	73K	144K	-94K	760K	1.83M	551K	1.7M	-173.04M
Effective Tax Rate %	100%	100%	100.11%	100.16%	99.91%	100.42%	101.72%	100.71%	77.23%	251.59%
Net Income+	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Net Margin %	-13465.32%	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Net Income Growth %	-25.19%	-203.89%	9.42%	-37.84%	-16.17%	-76.24%	40.22%	27.88%	107.37%	4893.08%
Net Income (Continuing)	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.66	-0.92	-0.76	-1.33	-0.87	-1.40	-0.76	-0.54	0.04	2.07
EPS Growth %	-13.79%	-39.39%	17.39%	-75%	34.59%	-60.92%	45.71%	28.95%	107.28%	5167.18%
EPS (Basic)	-0.66	-0.92	-0.76	-1.33	-0.87	-1.40	-0.76	-0.54	0.04	2.14
Diluted Shares Outstanding	35.28M	76.95M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	146.19M	138.7M
Basic Shares Outstanding	35.28M	76.92M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	143.06M	134.37M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	41.42M	175.25M	132.85M	315.14M	419.43M	513.32M	442.54M	424.8M	446.6M	491.97M
Cash & Short-Term Investments	39.65M	173.46M	125.86M	306.02M	398.33M	466.08M	389.39M	350.49M	358.48M	398M
Cash Only	39.65M	165.63M	117.97M	306.02M	272.35M	231.9M	94.17M	48.88M	83.43M	80.21M
Short-Term Investments	0	7.83M	7.89M	0	125.98M	234.18M	295.22M	301.61M	275.04M	317.78M
Accounts Receivable	86K	109K	217K	368K	0	15.41M	13.48M	24.09M	36.54M	41.45M
Days Sales Outstanding	181.45	94.73	171.07	422.39	-	123.37	36.72	50.1	56.73	53.45
Inventory	0	-109K	0	0	13.93M	19.33M	24.75M	39.7M	39.23M	45.69M
Days Inventory Outstanding	-	-	-	-	-	6.47K	1.6K	1.02K	506.88	510.54
Other Current Assets	0	0	0	0	1.02M	796K	1.33M	1.03M	1.13M	6.83M
Total Non-Current Assets+	15.58M	14.6M	13.02M	9.16M	44.23M	30.04M	28.32M	123.26M	104.05M	259.62M
Property, Plant & Equipment	29K	31K	41K	93K	10.28M	9.8M	8.56M	116.57M	98.87M	79.57M
Fixed Asset Turnover	5.97x	13.55x	11.29x	3.42x	4.88x	4.65x	15.66x	1.51x	2.38x	3.56x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	15.55M	14.12M	12.62M	8.86M	9.33M	8.4M	6.42M	4.98M	4.36M	3.76M
Long-Term Investments	0	0	0	0	24.38M	0	0	201K	0	0
Other Non-Current Assets	0	448K	358K	209K	247K	11.84M	13.34M	1.52M	823K	93K
Total Assets+	57M	189.85M	145.86M	324.3M	463.66M	543.37M	470.86M	548.06M	550.64M	751.59M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.11x	0.08x	0.28x	0.32x	0.43x	0.38x
Asset Growth %	69.8%	233.08%	-23.17%	122.33%	42.97%	17.19%	-13.34%	16.4%	0.47%	36.49%
Total Current Liabilities+	7.93M	8.15M	7.26M	11.29M	32M	40.65M	46.11M	77.19M	97.76M	93.72M
Accounts Payable	2.86M	3.77M	2.95M	4.15M	2.63M	3.88M	3.09M	4.33M	5.19M	3.31M
Days Payables Outstanding	261.25K	1000K	26.03	-	-	1.3K	198.93	111.63	67.02	37.02
Short-Term Debt	0	0	0	0	0	0	0	0	0	17.59M
Deferred Revenue (Current)	118K	118K	118K	118K	0	190K	3.15M	4.81M	11M	3.72M
Other Current Liabilities	3.78M	2.22M	1.92M	0	6.41M	4.45M	2.03M	1.59M	66.5M	72.41M
Current Ratio	5.22x	21.50x	18.30x	27.90x	13.11x	12.63x	9.60x	5.50x	4.57x	5.25x
Quick Ratio	5.22x	21.52x	18.30x	27.90x	12.67x	12.15x	9.06x	4.99x	4.17x	4.76x
Cash Conversion Cycle	-	-	-	-	-	5.29K	1.43K	962.8	496.58	526.98
Total Non-Current Liabilities+	13.12M	15.95M	26.03M	14.41M	23.91M	23.63M	19.32M	92.92M	75.4M	76.53M
Long-Term Debt	0	0	0	0	0	0	0	0	0	57.22M
Capital Lease Obligations	0	0	0	0	7.62M	7.68M	7.15M	82.01M	64.3M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.56M	15.51M	25.7M	14.2M	16.3M	15.95M	12.17M	10.91M	11.11M	19.31M
Total Liabilities	21.05M	24.1M	33.29M	25.7M	55.91M	64.28M	65.42M	170.11M	173.17M	170.26M
Total Debt+	0	0	0	0	8.41M	8.74M	8.09M	97.61M	79.37M	74.81M
Net Debt	-39.65M	-165.63M	-117.97M	-306.02M	-263.94M	-223.16M	-86.08M	48.73M	-4.06M	-5.4M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Debt / EBITDA	-	-	-	-	-	-	-	-	5.38x	0.71x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.28x	-0.05x
Interest Coverage	-	-	-	-	-	-	-	-33.04x	-0.97x	-
Total Equity+	35.95M	165.74M	112.58M	298.6M	407.75M	479.09M	405.44M	377.95M	377.48M	581.33M
Equity Growth %	80.08%	361.04%	-32.08%	165.25%	36.55%	17.5%	-15.37%	-6.78%	-0.13%	54%
Book Value per Share	1.02	2.15	1.33	3.21	3.44	3.70	2.86	2.64	2.58	4.19
Total Shareholders' Equity	35.95M	165.74M	112.58M	298.6M	407.75M	479.09M	405.44M	377.95M	377.48M	581.33M
Common Stock	299.81M	499.2M	504.65M	746.49M	944.33M	1.18B	1.19B	1.2B	1.19B	1.12B
Retained Earnings	-281.05M	-351.84M	-415.96M	-472.48M	-575.16M	-756.12M	-864.3M	-942.32M	-936.57M	-649.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-805K	-883K	-805K	-805K	-805K	-852K	-1.06M	-730K	-647K	-599K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-18.71M	-41.17M	-51.61M	-63.59M	-69.86M	-157.69M	-79.53M	-33.46M	44.39M	135.66M
Operating CF Margin %	-10816.76%	-9802.14%	-11146.87%	-19995.28%	-139.39%	-345.78%	-59.34%	-19.06%	18.88%	47.93%
Operating CF Growth %	-5.33%	-120%	-25.36%	-23.2%	-9.87%	-125.73%	49.57%	57.93%	232.66%	205.62%
Net Income	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Depreciation & Amortization	1.48M	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	9.27M
Stock-Based Compensation	1.38M	4.24M	6.86M	7.41M	17.45M	31.24M	32.3M	45.31M	31.6M	14.68M
Deferred Taxes	-1.75M	23.99M	9.97M	0	0	0	0	0	0	-176.19M
Other Non-Cash Items	2M	-1.77M	118K	14.19M	9.48M	10.9M	462K	-6.79M	-17.85M	702K
Working Capital Changes	1.47M	1.7M	-6M	2.03M	4.52M	-21.63M	-6.82M	-5.61M	5.45M	0
Change in Receivables	-39K	-23K	-108K	-151K	-13.62M	-15.41M	1.93M	-10.61M	-12.46M	-4.91M
Change in Inventory	0	0	0	0	-13.93M	-5.64M	-9.07M	-15.87M	477K	-6.46M
Change in Payables	2.46M	2.17M	-888K	0	13.62M	4.08M	-792K	1.24M	860K	-1.87M
Cash from Investing+	9.99M	-8M	-66K	7.78M	-158.19M	-103.87M	-60.63M	-6.71M	39.26M	-32.77M
Capital Expenditures	-25K	-25K	-75K	-85K	-7.34M	-1.5M	-292K	-718K	-281K	-252K
CapEx % of Revenue	14.45%	5.95%	16.2%	26.73%	14.65%	3.29%	0.22%	0.41%	0.12%	0.09%
Acquisitions	10K	0	45K	0	1.76M	-1.2M	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9K	-7.98M	-45K	-16K	-1.76M	-16.63M	-663K	-11.86M	-43K	0
Cash from Financing+	42.62M	175.15M	4.01M	243.85M	194.38M	221.11M	2.43M	-5.13M	-49.09M	-106.11M
Debt Issued (Net)	0	0	0	-127K	0	0	0	-10.03M	-11.99M	0
Equity Issued (Net)	1000K	1000K	0	1000K	1000K	1000K	0	0	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	-40.24M	-98.16M
Other Financing	34.79M	12.83M	4.01M	20.86M	6.64M	24.37M	2.43M	4.89M	3.14M	-106.11M
Net Change in Cash	33.89M	125.98M	-47.66M	188.05M	-33.67M	-40.45M	-137.73M	-45.3M	34.56M	-3.22M
Free Cash Flow+	-18.74M	-41.19M	-51.69M	-63.69M	-77.2M	-159.19M	-79.82M	-34.18M	44.11M	135.41M
FCF Margin %	-10831.21%	-9808.1%	-11163.07%	-20027.04%	-154.04%	-349.07%	-59.55%	-19.47%	18.76%	47.84%
FCF Growth %	-5.18%	-119.84%	-25.47%	-23.22%	-21.22%	-106.21%	49.86%	57.18%	229.05%	206.99%
FCF per Share	-0.53	-0.54	-0.61	-0.68	-0.65	-1.23	-0.56	-0.24	0.30	0.98
FCF Conversion (FCF/Net Income)	0.80x	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Interest Paid	0	0	0	59K	0	257K	1.98M	0	0	0
Taxes Paid	0	0	0	0	0	257K	1.98M	496K	2.18M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-83.33%	-70.2%	-46.08%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%	59.91%
Return on Invested Capital (ROIC)	-325.67%	-	-	-	-114.7%	-67.82%	-29.06%	-18.44%	-0.88%	16.58%
Gross Margin	97.69%	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Net Margin	-13465.32%	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Interest Coverage	-	-	-	-	-	-	-	-33.04x	-0.97x	-
FCF Conversion	0.80x	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Revenue Growth	-26.38%	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%

US Stock Screener

...

Aurinia Pharmaceuticals Inc. (AUPH) 10-Year Financial Performance & Capital Metrics

AUPH •

HealthcareBiotechnologyImmunology and Inflammation Therapies

Revenue $283M +20.4%
EBITDA $105M +610.9%
Net Income $287M +4893.1%
EPS (Diluted) 2.07 +5167.2%
Gross Margin 88.46% +0.5%
EBITDA Margin 37.06% +490.5%
Operating Margin 37.06% +1959.5%
Net Margin 101.47% +4047.7%
ROE 59.91% +3834.1%
ROIC 16.58% +1986.5%
Debt/Equity 0.13 -38.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 47.8% free cash flow margin
✓Strong 5Y sales CAGR of 41.4%
✓Share count reduced 5.1% through buybacks

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y103.27%

5Y41.38%

3Y28.3%

TTM20.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM4893.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM4615.26%

ROCE

10Y Avg-26.72%

5Y Avg-13.06%

3Y Avg-0.87%

Latest18.89%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	173K	420K	463K	318K	50.12M	45.6M	134.03M	175.51M	235.13M	283.06M
Revenue Growth %	-26.38%	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%
Cost of Goods Sold+	4K	1K	41.38M	0	0	1.09M	5.66M	14.15M	28.25M	32.66M
COGS % of Revenue	2.31%	0.24%	8937.8%	-	-	2.39%	4.23%	8.06%	12.01%	11.54%
Gross Profit+	169K	419K	-40.92M	318K	50.12M	44.51M	128.37M	161.37M	206.88M	250.39M
Gross Margin %	97.69%	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Gross Profit Growth %	-24.22%	147.93%	-9865.87%	100.78%	15660.38%	-11.18%	188.37%	25.71%	28.21%	21.03%
Operating Expenses+	22.98M	47.48M	56.62M	91.26M	154.41M	225.25M	239.84M	253.06M	211.57M	145.48M
OpEx % of Revenue	13284.97%	11305.24%	12229.16%	28698.43%	308.09%	493.91%	178.94%	144.18%	89.98%	51.4%
Selling, General & Admin	6.97M	12.1M	13.67M	22.34M	97.27M	171.44M	196.37M	195.04M	172.03M	101.79M
SG&A % of Revenue	4028.9%	2880%	2953.35%	7024.53%	194.09%	375.92%	146.51%	111.12%	73.16%	35.96%
Research & Development	14.53M	33.93M	41.38M	52.87M	50.33M	51.14M	44.99M	49.64M	20.79M	32.51M
R&D % of Revenue	8401.16%	8078.57%	8937.8%	16624.53%	100.42%	112.13%	33.57%	28.28%	8.84%	11.48%
Other Operating Expenses	-1.63M	195K	2.06M	16.06M	6.81M	2.67M	-1.52M	8.38M	18.76M	11.18M
Operating Income+	-22.81M	-47.06M	-56.16M	-90.94M	-104.29M	-180.74M	-111.47M	-91.69M	-4.69M	104.91M
Operating Margin %	-13187.28%	-11205.48%	-12129.16%	-28598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%	37.06%
Operating Income Growth %	3.25%	-106.29%	-19.33%	-61.94%	-14.68%	-73.3%	38.32%	17.74%	94.89%	2338.4%
EBITDA+	-21.34M	-45.61M	-54.59M	-89.77M	-102.92M	-177.97M	-108.76M	-80.04M	14.76M	104.91M
EBITDA Margin %	-12332.37%	-10858.81%	-11791.14%	-28230.19%	-205.35%	-390.25%	-81.15%	-45.61%	6.28%	37.06%
EBITDA Growth %	3.12%	-113.77%	-19.7%	-64.44%	-14.64%	-72.93%	38.89%	26.41%	118.44%	610.9%
D&A (Non-Cash Add-back)	1.48M	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	0
EBIT	-22.81M	-47.06M	-55.91M	-90.94M	-104.29M	-180.21M	-106.35M	-74.69M	12.28M	0
Net Interest Income+	27K	1.04M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	0
Interest Income	27K	1.04M	2.23M	2.7M	1.52M	529K	5.12M	17M	16.97M	13.57M
Interest Expense	0	0	0	0	0	0	0	2.77M	4.83M	-4.33M
Other Income/Expense	-481K	-23.73M	2.23M	2.7M	1.52M	529K	5.12M	14.22M	12.13M	9.24M
Pretax Income+	-23.3M	-70.79M	-64.05M	-88.24M	-102.77M	-180.21M	-106.35M	-77.47M	7.45M	114.16M
Pretax Margin %	-13465.32%	-16855.24%	-13833.05%	-27748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%	40.33%
Income Tax+	0	0	73K	144K	-94K	760K	1.83M	551K	1.7M	-173.04M
Effective Tax Rate %	100%	100%	100.11%	100.16%	99.91%	100.42%	101.72%	100.71%	77.23%	251.59%
Net Income+	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Net Margin %	-13465.32%	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Net Income Growth %	-25.19%	-203.89%	9.42%	-37.84%	-16.17%	-76.24%	40.22%	27.88%	107.37%	4893.08%
Net Income (Continuing)	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.66	-0.92	-0.76	-1.33	-0.87	-1.40	-0.76	-0.54	0.04	2.07
EPS Growth %	-13.79%	-39.39%	17.39%	-75%	34.59%	-60.92%	45.71%	28.95%	107.28%	5167.18%
EPS (Basic)	-0.66	-0.92	-0.76	-1.33	-0.87	-1.40	-0.76	-0.54	0.04	2.14
Diluted Shares Outstanding	35.28M	76.95M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	146.19M	138.7M
Basic Shares Outstanding	35.28M	76.92M	84.78M	93.02M	118.47M	129.37M	141.91M	143.24M	143.06M	134.37M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	41.42M	175.25M	132.85M	315.14M	419.43M	513.32M	442.54M	424.8M	446.6M	491.97M
Cash & Short-Term Investments	39.65M	173.46M	125.86M	306.02M	398.33M	466.08M	389.39M	350.49M	358.48M	398M
Cash Only	39.65M	165.63M	117.97M	306.02M	272.35M	231.9M	94.17M	48.88M	83.43M	80.21M
Short-Term Investments	0	7.83M	7.89M	0	125.98M	234.18M	295.22M	301.61M	275.04M	317.78M
Accounts Receivable	86K	109K	217K	368K	0	15.41M	13.48M	24.09M	36.54M	41.45M
Days Sales Outstanding	181.45	94.73	171.07	422.39	-	123.37	36.72	50.1	56.73	53.45
Inventory	0	-109K	0	0	13.93M	19.33M	24.75M	39.7M	39.23M	45.69M
Days Inventory Outstanding	-	-	-	-	-	6.47K	1.6K	1.02K	506.88	510.54
Other Current Assets	0	0	0	0	1.02M	796K	1.33M	1.03M	1.13M	6.83M
Total Non-Current Assets+	15.58M	14.6M	13.02M	9.16M	44.23M	30.04M	28.32M	123.26M	104.05M	259.62M
Property, Plant & Equipment	29K	31K	41K	93K	10.28M	9.8M	8.56M	116.57M	98.87M	79.57M
Fixed Asset Turnover	5.97x	13.55x	11.29x	3.42x	4.88x	4.65x	15.66x	1.51x	2.38x	3.56x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	15.55M	14.12M	12.62M	8.86M	9.33M	8.4M	6.42M	4.98M	4.36M	3.76M
Long-Term Investments	0	0	0	0	24.38M	0	0	201K	0	0
Other Non-Current Assets	0	448K	358K	209K	247K	11.84M	13.34M	1.52M	823K	93K
Total Assets+	57M	189.85M	145.86M	324.3M	463.66M	543.37M	470.86M	548.06M	550.64M	751.59M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.11x	0.08x	0.28x	0.32x	0.43x	0.38x
Asset Growth %	69.8%	233.08%	-23.17%	122.33%	42.97%	17.19%	-13.34%	16.4%	0.47%	36.49%
Total Current Liabilities+	7.93M	8.15M	7.26M	11.29M	32M	40.65M	46.11M	77.19M	97.76M	93.72M
Accounts Payable	2.86M	3.77M	2.95M	4.15M	2.63M	3.88M	3.09M	4.33M	5.19M	3.31M
Days Payables Outstanding	261.25K	1000K	26.03	-	-	1.3K	198.93	111.63	67.02	37.02
Short-Term Debt	0	0	0	0	0	0	0	0	0	17.59M
Deferred Revenue (Current)	118K	118K	118K	118K	0	190K	3.15M	4.81M	11M	3.72M
Other Current Liabilities	3.78M	2.22M	1.92M	0	6.41M	4.45M	2.03M	1.59M	66.5M	72.41M
Current Ratio	5.22x	21.50x	18.30x	27.90x	13.11x	12.63x	9.60x	5.50x	4.57x	5.25x
Quick Ratio	5.22x	21.52x	18.30x	27.90x	12.67x	12.15x	9.06x	4.99x	4.17x	4.76x
Cash Conversion Cycle	-	-	-	-	-	5.29K	1.43K	962.8	496.58	526.98
Total Non-Current Liabilities+	13.12M	15.95M	26.03M	14.41M	23.91M	23.63M	19.32M	92.92M	75.4M	76.53M
Long-Term Debt	0	0	0	0	0	0	0	0	0	57.22M
Capital Lease Obligations	0	0	0	0	7.62M	7.68M	7.15M	82.01M	64.3M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.56M	15.51M	25.7M	14.2M	16.3M	15.95M	12.17M	10.91M	11.11M	19.31M
Total Liabilities	21.05M	24.1M	33.29M	25.7M	55.91M	64.28M	65.42M	170.11M	173.17M	170.26M
Total Debt+	0	0	0	0	8.41M	8.74M	8.09M	97.61M	79.37M	74.81M
Net Debt	-39.65M	-165.63M	-117.97M	-306.02M	-263.94M	-223.16M	-86.08M	48.73M	-4.06M	-5.4M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Debt / EBITDA	-	-	-	-	-	-	-	-	5.38x	0.71x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.28x	-0.05x
Interest Coverage	-	-	-	-	-	-	-	-33.04x	-0.97x	-
Total Equity+	35.95M	165.74M	112.58M	298.6M	407.75M	479.09M	405.44M	377.95M	377.48M	581.33M
Equity Growth %	80.08%	361.04%	-32.08%	165.25%	36.55%	17.5%	-15.37%	-6.78%	-0.13%	54%
Book Value per Share	1.02	2.15	1.33	3.21	3.44	3.70	2.86	2.64	2.58	4.19
Total Shareholders' Equity	35.95M	165.74M	112.58M	298.6M	407.75M	479.09M	405.44M	377.95M	377.48M	581.33M
Common Stock	299.81M	499.2M	504.65M	746.49M	944.33M	1.18B	1.19B	1.2B	1.19B	1.12B
Retained Earnings	-281.05M	-351.84M	-415.96M	-472.48M	-575.16M	-756.12M	-864.3M	-942.32M	-936.57M	-649.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-805K	-883K	-805K	-805K	-805K	-852K	-1.06M	-730K	-647K	-599K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-18.71M	-41.17M	-51.61M	-63.59M	-69.86M	-157.69M	-79.53M	-33.46M	44.39M	135.66M
Operating CF Margin %	-10816.76%	-9802.14%	-11146.87%	-19995.28%	-139.39%	-345.78%	-59.34%	-19.06%	18.88%	47.93%
Operating CF Growth %	-5.33%	-120%	-25.36%	-23.2%	-9.87%	-125.73%	49.57%	57.93%	232.66%	205.62%
Net Income	-23.3M	-70.79M	-64.12M	-88.39M	-102.68M	-180.97M	-108.18M	-78.02M	5.75M	287.2M
Depreciation & Amortization	1.48M	1.46M	1.56M	1.17M	1.37M	2.76M	2.71M	11.65M	19.45M	9.27M
Stock-Based Compensation	1.38M	4.24M	6.86M	7.41M	17.45M	31.24M	32.3M	45.31M	31.6M	14.68M
Deferred Taxes	-1.75M	23.99M	9.97M	0	0	0	0	0	0	-176.19M
Other Non-Cash Items	2M	-1.77M	118K	14.19M	9.48M	10.9M	462K	-6.79M	-17.85M	702K
Working Capital Changes	1.47M	1.7M	-6M	2.03M	4.52M	-21.63M	-6.82M	-5.61M	5.45M	0
Change in Receivables	-39K	-23K	-108K	-151K	-13.62M	-15.41M	1.93M	-10.61M	-12.46M	-4.91M
Change in Inventory	0	0	0	0	-13.93M	-5.64M	-9.07M	-15.87M	477K	-6.46M
Change in Payables	2.46M	2.17M	-888K	0	13.62M	4.08M	-792K	1.24M	860K	-1.87M
Cash from Investing+	9.99M	-8M	-66K	7.78M	-158.19M	-103.87M	-60.63M	-6.71M	39.26M	-32.77M
Capital Expenditures	-25K	-25K	-75K	-85K	-7.34M	-1.5M	-292K	-718K	-281K	-252K
CapEx % of Revenue	14.45%	5.95%	16.2%	26.73%	14.65%	3.29%	0.22%	0.41%	0.12%	0.09%
Acquisitions	10K	0	45K	0	1.76M	-1.2M	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9K	-7.98M	-45K	-16K	-1.76M	-16.63M	-663K	-11.86M	-43K	0
Cash from Financing+	42.62M	175.15M	4.01M	243.85M	194.38M	221.11M	2.43M	-5.13M	-49.09M	-106.11M
Debt Issued (Net)	0	0	0	-127K	0	0	0	-10.03M	-11.99M	0
Equity Issued (Net)	1000K	1000K	0	1000K	1000K	1000K	0	0	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	-40.24M	-98.16M
Other Financing	34.79M	12.83M	4.01M	20.86M	6.64M	24.37M	2.43M	4.89M	3.14M	-106.11M
Net Change in Cash	33.89M	125.98M	-47.66M	188.05M	-33.67M	-40.45M	-137.73M	-45.3M	34.56M	-3.22M
Free Cash Flow+	-18.74M	-41.19M	-51.69M	-63.69M	-77.2M	-159.19M	-79.82M	-34.18M	44.11M	135.41M
FCF Margin %	-10831.21%	-9808.1%	-11163.07%	-20027.04%	-154.04%	-349.07%	-59.55%	-19.47%	18.76%	47.84%
FCF Growth %	-5.18%	-119.84%	-25.47%	-23.22%	-21.22%	-106.21%	49.86%	57.18%	229.05%	206.99%
FCF per Share	-0.53	-0.54	-0.61	-0.68	-0.65	-1.23	-0.56	-0.24	0.30	0.98
FCF Conversion (FCF/Net Income)	0.80x	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Interest Paid	0	0	0	59K	0	257K	1.98M	0	0	0
Taxes Paid	0	0	0	0	0	257K	1.98M	496K	2.18M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-83.33%	-70.2%	-46.08%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%	59.91%
Return on Invested Capital (ROIC)	-325.67%	-	-	-	-114.7%	-67.82%	-29.06%	-18.44%	-0.88%	16.58%
Gross Margin	97.69%	99.76%	-8837.8%	100%	100%	97.61%	95.77%	91.94%	87.99%	88.46%
Net Margin	-13465.32%	-16855.24%	-13848.81%	-27794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.26x	0.21x	0.13x
Interest Coverage	-	-	-	-	-	-	-	-33.04x	-0.97x	-
FCF Conversion	0.80x	0.58x	0.80x	0.72x	0.68x	0.87x	0.74x	0.43x	7.72x	0.47x
Revenue Growth	-26.38%	142.77%	10.24%	-31.32%	15660.38%	-9%	193.89%	30.95%	33.97%	20.38%

Aurinia Pharmaceuticals Inc. (AUPH) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AUPH vs Peers

vs ARGX

vs CANF

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Aurinia Pharmaceuticals Inc. (AUPH) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AUPH vs Peers

vs ARGX

vs CANF

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios